Evidence map›Paper›PMID 42420752›Full record

ArticleThe Journal of pathology2026

Immune dysregulation in the prostates of C57BL/6

Nadia A Lanman, Meaghan M Broman, Harish Kothandaraman, Gregory M Cresswell, Gada D Awdalkreem, Dilinaer Wusiman, Andree K Kolliegbo, Alexander P Glaser, Brian T Helfand, Renee E Vickman and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Nadia A LanmanDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA.ORCID https://orcid.org/0000-0002-1819-7070
Meaghan M BromanDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA.
Harish KothandaramanPurdue University Institute for Cancer Research, Purdue University, West Lafayette, IN, USA.ORCID https://orcid.org/0000-0002-0759-4601
Gregory M CresswellDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA.
Gada D AwdalkreemDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA.
Dilinaer WusimanDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA.
Andree K KolliegboPurdue University Institute for Cancer Research, Purdue University, West Lafayette, IN, USA.
Alexander P GlaserDivision of Urology, Department of Surgery, Endeavor Health Research Institute, Evanston, IL, USA.
Brian T HelfandDivision of Urology, Department of Surgery, Endeavor Health Research Institute, Evanston, IL, USA.
Renee E VickmanUniversity of Chicago Pritzker School of Medicine, Chicago, IL, USA.ORCID https://orcid.org/0000-0002-5614-9221
Jiang YangDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA.
Simon W HaywardUniversity of Chicago Pritzker School of Medicine, Chicago, IL, USA.
Timothy L RatliffDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA.

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
Impact of Inflammation on Adult Prostate Stem CellsR01DK126478 · NIDDK · PURDUE UNIVERSITY · PI RATLIFF, TIMOTHY L. · 2020 to 2023
$2.4M
Validating Mouse Models of Prostatic HyperplasiaP20DK140417 · NIDDK · ENDEAVOR HEALTH CLINICAL OPERATIONS · PI Simon W Hayward · 2024 to 2026
$1.6M
NCI NIH HHS P30 CA023168NCI NIH HHS P30CA023168NCI NIH HHS P30 CA082709NIDDK NIH HHS P20 DK140417NIDDK NIH HHS P20DK140417NIDDK NIH HHS R01 DK126478NIDDK NIH HHS R01-DK126478Purdue University Institute for Cancer Research P30CA082709
6 · The paper itself

Abstract

Benign prostatic hyperplasia (BPH) is the most common urologic disease in aging men, resulting in significant morbidity. The etiologies of BPH are unknown, though chronic prostatic inflammation is known to promote hyperplasia, fibrotic remodeling, and therapeutic resistance in BPH. BPH is highly complex and heterogeneous, presenting with varying degrees of stromal and epithelial proliferation, fibrosis, inflammation, and associated lower urinary tract symptoms. This complexity poses challenges in developing models. Here, we characterize an Aire transcription factor-deficient nonresolving (chronic) inflammation model in a C57BL/6J background for the study of the prostatic inflammation present in BPH. This chronic inflammatory model exhibits a lack of central tolerance but retains an otherwise intact and functional immune system. C57BL/6

Indexed as

ProstateProstatic HyperplasiaProstatitisAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMice, KnockoutTranscription FactorsTranscription FactorsagingAireBPHinflammaginginflammationprostatescRNA‐seq

Identifiers

PMID42420752
PMCPMC13576882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.